Danaher's (DHR -0.1%) subsidiary Beckman Coulter says the FDA has granted 510(k) clearance to...

Danaher's (DHR -0.1%) subsidiary Beckman Coulter says the FDA has granted 510(k) clearance to its new Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system, designed to assist physicians with the diagnosis of heart attacks.